BOT - Anything but charting, page-6667

So, if the US simply follows Japan and sells $239m at say only 50% profit, that equates to $119m profit per annum, divided by 1.5B shares and times a PE multiple of 10 = $0.79 per share. And that's ultra conservative based on only a PE of 10, only 50% profit, not taking into account a 3 times US population, and not giving any value whatsoever to BOT's successful pipeline in the background.

Dare to dream of a more likely biotech PE of 20 times ($1.60/share), BOT selling three times as well as Japan because of higher population ($4.80), the year-on-year growth, PLUS just one product from the pipeline to achieve FDA approval, and we're easily looking at +$5 within a few short years! But I doubt BOT will get that far before being taken out by big pharma. Hard not to be excited about BOT!